← Eichor
Condition: Cancer Solid Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cancer Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT06907043An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Guangzhou FineImmune Biotechnology Co., LTD. · NCT06942143APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT07489378Study of ESG406 in Adults With Solid Tumors
Phase 1 · 3 location(s) · Shanghai Escugen Biotechnology Co., Ltd · NCT06979674PumaRx Registry Trial
Phase N/A · 3 location(s) · RenovoRx · NCT06805461A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 22 location(s) · Sanofi · NCT05584670A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Phase 1 · 9 location(s) · PAQ Therapeutics, Inc. · NCT07300150Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Phase 1/Phase 2 · 2 location(s) · Nanjing Immunophage Biotech Co., Ltd · NCT06212076A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
Phase 1/Phase 2 · 6 location(s) · Carrick Therapeutics Limited · NCT06600789A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shanghai Shengdi Pharmaceutical Co., Ltd · NCT07231211Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05178472A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06475300A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Crossignal Therapeutics, Inc. · NCT06598007EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combinatio
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT07262619A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 · 40 location(s) · Pfizer · NCT05355701HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT07296341SKB105 for Injection in Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · NCT07380386DXP-106 in Solid Tumor Patients.
Phase 1 · 3 location(s) · Singlomics Biopharmaceuticals Zhuhai Co., Ltd. · NCT07532018Sapu003 in Advanced mTOR-sensitive Solid Tumors
Phase 1 · 1 location(s) · SAPU NANO (US) LLC · NCT07369505First In Human Study of CX-2051 in Advanced Solid Tumors
Phase 1 · 8 location(s) · CytomX Therapeutics · NCT06265688A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · 62 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo
Phase 1/Phase 2 · 71 location(s) · Merck Sharp & Dohme LLC · NCT06395103Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Phase 1 · 1 location(s) · Sichuan University · NCT06084286A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Phase 1 · 21 location(s) · Bristol-Myers Squibb · NCT06997029A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Phase 1 · 4 location(s) · Hangzhou DAC Biotechnology Co., Ltd. · NCT06926283Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Diseas
Phase N/A · 1 location(s) · Hospital Universitario Araba · NCT07249060A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
Phase 1/Phase 2 · 1 location(s) · 3H Pharmaceuticals Co., Ltd. · NCT07354711HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · 11 location(s) · Hutchmed · NCT07396584
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.